

# Endometrial cancer prognosis in women with endometriosis and adenomyosis. A retrospective nationwide cohort study of 40,840 women.

Marjolein Hermens MD, Anne M van Altena MD PhD, Maaike van der Aa PhD, Johan Bulten MD PhD, Huib AAM van Vliet MD PhD, Albert G Siebers PhD, Ruud LM Bekkers MD PhD

## **Supplemental material table of contents**

Supplemental table 1	page 2
Supplemental table 2	page 3
Supplemental figure 1	page 4
Supplemental figure 2	page 5

**Supplemental table 1 Baseline characteristics for patients included in the Cox proportional hazard analysis.**

	<b>Endometriosis (n=294)</b>	<b>Adenomyosis (n=1,125)</b>	<b>Endometriosis and adenomyosis (n=138)</b>	<b>No endometriosis or adenomyosis (n=33,985)</b>
<b>Age at endometrial cancer diagnosis in years (IQR)<sup>a</sup></b>	60 (IQR 53-68)	62 (IQR 55-70)	57 (IQR 52-65)	66 (IQR 59-75)
<b>Year of diagnosis (IQR)<sup>b</sup></b>	2004 (IQR 1997-2010)	2004 (IQR 1996-2009)	2004 (IQR 1997-2010)	2004 (IQR 1997-2010)
<b>Endometrial cancer stage<sup>a</sup></b>				
Stage 1	240 (81.6%)	1,033 (91.8%)	117 (84.8%)	26,693 (78.5%)
Stage 2	27 (9.2%)	43 (3.8%)	9 (6.5%)	2,791 (8.2%)
Stage 3	18 (6.1%)	41 (3.6%)	10 (7.2%)	2,909 (8.6%)
Stage 4	9 (3.1%)	8 (0.7%)	2 (1.4%)	1,592 (4.7%)
<b>Histological tumor type<sup>a</sup></b>				
Endometrioid	170 (57.8%)	610 (54.2%)	76 (55.1%)	18,599 (54.7%)
Clear cell	0 (0.0%)	10 (0.9%)	0 (0.0%)	482 (1.4%)
Serous	6 (2.0%)	13 (1.2%)	0 (0.0%)	951 (2.8%)
Mucinous	5 (1.7%)	8 (0.7%)	1 (0.7%)	286 (0.8%)
Adenocarcinoma NOS	113 (38.4%)	484 (43.0%)	61 (44.2%)	13,668 (40.2%)
<b>Histological grading<sup>a</sup></b>				
Low	156 (53.1%)	657 (58.4%)	92 (66.7%)	15,035 (44.2%)
Intermediate	90 (30.6%)	335 (29.8%)	39 (28.3%)	12,098 (35.6%)
High	48 (16.3%)	133 (11.8%)	7 (5.1%)	6,714 (19.8%)
<b>Surgery<sup>a</sup></b>				
Yes	282 (95.9%)	1,119 (99.5%)	137 (99.3%)	32,532 (95.7%)
No	12 (4.1%)	6 (0.5%)	1 (0.7%)	1,453 (4.3%)
<b>Chemotherapy<sup>a</sup></b>				
Yes	15 (5.1%)	15 (1.3%)	4 (2.9%)	1,128 (3.3%)
No	279 (94.9%)	1,110 (98.7%)	134 (97.1%)	32,857 (96.7%)
<b>Vital status as of January 31, 2020<sup>a</sup></b>				
Alive	175 (59.5%)	664 (59.0%)	96 (69.6%)	16,424 (48.3%)
Passed away	119 (40.5%)	461 (41.0%)	42 (30.4%)	17,561 (51.7%)

Data are in numbers (percentage) unless otherwise specified. IQR = interquartile range, NOS= Not Otherwise Specified

<sup>a</sup> p<0.005 for comparison between patients with endometrial cancer with histological proven endometriosis and /or adenomyosis and those without.

<sup>b</sup> p value not statistically significant for comparison between patients with endometrial cancer with histological proven endometriosis and / or adenomyosis and those without.

**Supplemental table 2 Hazard ratios of overall survival among women with endometrial cancer in univariable and multivariable analysis (n=35,542).**


	<b>Univariable analysis Hazard Ratio (95%CI)</b>	<b>Multivariable analysis Hazard Ratio (95%CI)</b>
<b>Endometriosis/adenomyosis</b>	0.63 (0.59-0.69) <sup>b</sup>	0.98 (0.90-1.06) <sup>c</sup>
<b>Age</b>	1.09 (1.08-1.09) <sup>b</sup>	1.08 (1.08-1.08) <sup>b</sup>
<b>Endometrial cancer stage<sup>a</sup></b>		
Stage 1	1.00 (ref)	1.00 (ref)
Stage 2	1.64 (1.56-1.72) <sup>b</sup>	1.40 (1.33-1.47) <sup>b</sup>
Stage 3	2.69 (2.57-2.81) <sup>b</sup>	2.31 (2.20-2.42) <sup>b</sup>
Stage 4	7.38 (6.98-7.80) <sup>b</sup>	4.23 (3.95-4.52) <sup>b</sup>
<b>Histological tumor type<sup>a</sup></b>		
Endometrioid	1.00 (ref)	1.00 (ref)
Clear cell	2.12 (1.91-2.37) <sup>b</sup>	1.10 (0.98-1.23) <sup>b</sup>
Serous	3.13 (2.89-3.38) <sup>b</sup>	1.25 (1.14-1.36) <sup>b</sup>
Mucinous	1.28 (1.10-1.48) <sup>b</sup>	1.04 (0.90-1.21) <sup>b</sup>
Adenocarcinoma NOS	1.29 (1.25-1.33) <sup>b</sup>	1.20 (1.16-1.24) <sup>b</sup>
<b>Histological grading<sup>a</sup></b>		
Low	1.00 (ref)	1.00 (ref)
Intermediate	1.48 (1.43-1.53) <sup>b</sup>	1.21 (1.17-1.25) <sup>b</sup>
High	2.65 (2.56-2.76) <sup>b</sup>	1.71 (1.64-1.78) <sup>b</sup>
<b>Surgery</b>	0.14 (0.13-0.15) <sup>b</sup>	0.39 (0.36-0.41) <sup>b</sup>
<b>Chemotherapy</b>	2.56 (2.39-2.75) <sup>b</sup>	1.22 (1.12-1.32) <sup>b</sup>

Only significant factors in univariable analysis are displayed.

NOS = not otherwise specified.

<sup>a</sup>p-value < 0.0005 for categorical factor in univariable and multivariable analyses. <sup>b</sup>p-value < 0.0005. <sup>c</sup>p-value not statistically significant.

**Supplemental figure 1 Kaplan-Meier curve of overall survival, by endometriosis/adenomyosis status (binary).**



**Supplemental figure 2 Kaplan-Meier curve of overall survival, by endometriosis/adenomyosis status (binary) per low/high stage disease and histological subtype.**

